| Market Cap | ₹2,520.27 CrPharmaceuticals |
|---|---|
| Revenue TTM | ₹1,735.0 CrOperating Revenue |
| P/E Ratio | -74.56TTM Basis |
| Promoter Holding | 68.85%No pledge |
Key highlights
- Swissmedic grants Certificate of GMP Compliance to Hikal's Bengaluru API facility
- Certification aligns with the Mutual Recognition Agreement between Switzerland and the European Union
- Approval enables the facility to serve a wider customer base across regulated European markets
- Bengaluru site now holds recognitions from Swissmedic, Brazil’s ANVISA, and Japan’s PMDA
- Company maintains annual CapEx guidance of ₹200 crore for regulatory and capacity upgrades
Strategic Regulatory Milestone in Bengaluru
Hikal Limited announced on October 30, 2026, that Swissmedic, the Swiss Agency for Therapeutic Products, has certified its Bengaluru-based active pharmaceutical ingredient (API) facility. This Certificate of GMP Compliance signifies that the plant meets stringent standards under the Mutual Recognition Agreement between the European Union and Switzerland. For Hikal, which reported a June 2026 quarterly revenue of ₹402.8 crore, this approval serves as a critical gateway for exporting high-quality ingredients into the European pharmaceutical supply chain.
The site now joins an elite group of facilities approved by major global health regulators, supporting the company's efforts to scale its pharmaceutical division.
Expansion into Regulated Global Markets
- The Swissmedic certification reinforces the site standing alongside prior approvals from Brazils ANVISA and Japans PMDA
- Hikal aims to diversify its geographic footprint to mitigate risks from geopolitical and trade uncertainties
- The facility expansion into regulated markets supports the company long-term business strategy through 2030
- Quality systems at the Jigani Bengaluru plant are now validated for supply across the European continent
- The company reported a net profit loss of ₹7.4 crore for the quarter ended June 30, 2026
Management on Quality Endorsement
The Swissmedic certification is a strong endorsement of the quality systems at our Bengaluru facility. It is an important step in expanding the global reach of our pharmaceutical business and opens new opportunities with customers in Europe and other regulated markets.
Operational Roadmap and Capital Expenditure
Beyond this regulatory milestone, Hikal is pursuing an aggressive growth path with a targeted ₹500 crore revenue from Personal Care and ₹400 crore from Animal Health by FY30. To support these goals, the firm has maintained an annual capital expenditure guidance of approximately ₹200 crore, specifically allocated for debottlenecking, CDMO capacity expansion, and further regulatory upgrades. While the company faced a 22.4 percent sequential decline in quarterly revenue, the addition of the Swissmedic certification provides a structural advantage for future contract manufacturing opportunities in the specialty chemicals and pharmaceutical sectors.
Net profit for the latest quarter showed a 67 percent year-on-year improvement despite the sequential loss.
What to watch next
- Board meeting to approve Q2 and H1 FY27 financial results on November 3, 2026
- Implementation of ₹200 crore annual CapEx for capacity expansion and regulatory debottlenecking
- Progress toward the FY30 target of ₹400+ crore in Animal Health segment revenue
| Share price | ₹204.4 |
|---|---|
| Market capitalisation | ₹2,520.27 Cr |
| Revenue (annual) | ₹1,712.60 Cr |
| Net profit (annual) | -₹48.80 Cr |
| Revenue (latest quarter) | ₹402.80 Cr-22.45% vs previous quarter |
| Net profit (latest quarter) | -₹7.40 Cr-151.39% vs previous quarter |
| P/E (TTM) | -74.56×Sector 48.73× |
| Promoter holding | 68.85%0.00% QoQ |
| FII holding | 1.28%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by Hikal Ltd announcing Swissmedic GMP certification for its Bengaluru plant. Market figures from a third-party data provider.
